BackgroundCheck.run
Search For

Kerry L Campbell, 51Philadelphia, PA

Known as:
Kerry A Campbell Kerrya Campbell
Related to:
Doris Glasby Brian Campbell 61 Mary Campbell 53 Naomi Campbell Doris Glasby 87 Etux Campbell Kathleen Campbell 60 Eileen Campbell-Kelly 81 Craig Campbell 69 Damon Campbell 45 K Hubert Calvin Louis 57 Wm Campbell Jason Campbell 45 Amy Campbell 53 Kathleen Campell 73 Laurie Campbell 47 Karen Hubert 60 Sanford Campbell Karen Hubert 50 Maureen Campbell 86 Marlene Campbell 67 Deirdre Campbell 52 Paula Black 59 William Campbell 54 Barbara Campbell 76 Debra Powell 65 Amy Campbell 48 Earl Glasby 94 Rhonda Son 63 Kimberly Campbell 51 Mary Tharp 85 Robin Campbell 61 William Campbell Angela Jones-Anderson 54

Kerry Campbell Phones & Addresses

Philadelphia, PA   

22 Henchman St, Boston, MA 02113    617-5236554   

3 Magda Ln, Hillsborough, NJ 08844    908-6929374   

Somerville, NJ   

New York, NY   

Somerville, MA   

Ardmore, PA   

Florissant, MO   

Normandy Beach, NJ   

Get Report
Control this profile

Mentions for Kerry L Campbell

Career records & work history

Medicine Doctors

Kerry J. Campbell

Specialties:
General Practice
Work:
Swope Health Services
3801 Blue Pkwy, Kansas City, MO 64130
816-9235800 (phone) 816-5995967 (fax)
Site
Languages:
English, Spanish
Description:
Ms. Campbell works in Kansas City, MO and specializes in General Practice. Ms. Campbell is affiliated with Research Medical Center and Truman Medical Center-Lakewood.

License Records

Kerry P Campbell

Licenses:
License #: 41239 - Active
Category: EMS Licensing
Issued Date: Dec 30, 2015
Expiration Date: Jun 30, 2018
Type: EMT-Paramedic

Kerry Ann Campbell

Address:
New York, NY 10075
Licenses:
License #: TLRN028842 - Expired
Category: Nursing
Type: Registered Nurse Temporary Permit

Kerry Ann Campbell

Address:
Philadelphia, PA 19102
Licenses:
License #: RN601692 - Expired
Category: Nursing
Type: Registered Nurse

Kerry Campbell resumes & CV records

Resumes

Kerry Campbell Photo 50

Member

Location:
2 Hemlock Ln, Wyncote, PA 19095
Industry:
Biotechnology
Work:
Thomas Jefferson University Hospitals
Adjunct Associate Professor Basel Institute For Immunology/Hoffman La Roche Sep 1992 - May 1998
Member National Jewish Center For Immunology Feb 1988 - Aug 1992
Postdoctoral Associate Fox Chase Cancer Center Feb 1988 - Aug 1992
Member
Education:
Virginia Commonwealth University School of Medicine 1983 - 1988
The University of Toledo 1978 - 1983
Bachelors, Bachelor of Science, Pharmacy
Skills:
Cell, Cell Biology, Biochemistry, Flow Cytometry, Cancer, Molecular Biology, Immunology, Cancer Research, Cell Culture, Translational Research, Biotechnology, Tissue Culture, Western Blotting, Oncology, In Vivo, Clinical Research, Elisa, Pharmacology, Medical Education, Lifesciences
Kerry Campbell Photo 51

Kerry Campbell

Kerry Campbell Photo 52

Kerry Campbell

Kerry Campbell Photo 53

Kerry Campbell

Kerry Campbell Photo 54

Kerry Campbell

Kerry Campbell Photo 55

Kerry Campbell

Kerry Campbell Photo 56

Kerry Campbell

Kerry Campbell Photo 57

Kerry Campbell

Skills:
Microsoft Office, Customer Service, Powerpoint, Microsoft Excel, Microsoft Word, English, Strategic Planning, Public Relations, Training, Public Speaking, Editing

Publications & IP owners

Us Patents

Genetically Modified Human Natural Killer Cell Lines

US Patent:
8313943, Nov 20, 2012
Filed:
Sep 22, 2009
Appl. No.:
12/564283
Inventors:
Kerry S. Campbell - Wyncote PA, US
Assignee:
Fox Chase Cancer Center - Philadelphia PA
International Classification:
C12N 5/00
C12N 5/08
C07K 1/00
US Classification:
435325, 435366, 435372, 4353722
Abstract:
The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (FcγRIII-A), or other Fcγ or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as FcεRI-γ, TCR-ζ, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.

Genetically Modified Human Natural Killer Cell Lines

US Patent:
2006029, Dec 28, 2006
Filed:
Jul 8, 2005
Appl. No.:
11/178258
Inventors:
Kerry Campbell - Wyncote PA, US
International Classification:
A61K 39/395
G01N 33/574
C12N 5/08
US Classification:
424155100, 435007230, 435366000
Abstract:
The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD 16 (FcγRIII-A), or other Fcγ or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as FcεRI-γ,TCR-ζ, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.

Genetically Modified Human Natural Killer Cell Lines

US Patent:
2008024, Oct 9, 2008
Filed:
Apr 21, 2008
Appl. No.:
12/106665
Inventors:
Kerry S. Campbell - Wyncote PA, US
Assignee:
Fox Chase Cancer Center - Philadelphia PA
International Classification:
A61K 38/20
C12N 5/06
G01N 33/566
A61K 39/395
US Classification:
424 852, 435325, 435 721, 4241721, 4241331, 4241741, 4241551
Abstract:
The invention provides a natural killer cell, NK-92, modified to express a CD16 receptor or an inhibitory killer cell immunoglobulin-like receptor (KIR) on a surface of the cell. In examples, the NK-92 cell is further modified to co-express an associated accessory signaling protein such as FcεRI-γ or TCR-ζ, chemokines, or cytokines such as interleukin-2 (IL-2) or interleukin-15 (IL-15). Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.

Genetically Modified Human Natural Killer Cell Lines

US Patent:
2010008, Apr 8, 2010
Filed:
Sep 22, 2009
Appl. No.:
12/564255
Inventors:
KERRY S. CAMPBELL - WYNCOTE PA, US
Assignee:
FOX CHASE CANCER CENTER - PHILADELPHIA PA
International Classification:
A61K 49/00
C12N 5/00
C12Q 1/18
G01N 33/53
A61K 39/395
A61P 35/00
A61P 31/00
A61K 38/20
US Classification:
424 92, 435325, 435 32, 435 72, 4241301, 4241411, 4241331, 424 852
Abstract:
The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (FcγRIII-A), or other Fcγ or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as FcεRI-γ, TCR-ζ, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.

Genetically Modified Human Natural Killer Cell Lines

US Patent:
2013004, Feb 14, 2013
Filed:
Oct 15, 2012
Appl. No.:
13/651797
Inventors:
FOX CHASE CANCER CENTER - Philadelphia PA, US
Kerry S. Campbell - Wyncote PA, US
Assignee:
FOX CHASE CANCER CENTER - Philadelphia PA
International Classification:
C12N 5/10
US Classification:
435325
Abstract:
The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (FcγRIII-A), or other Fcγ or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as FcεRI-γ, TCR-ζ, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.

Genetically Modified Human Natural Killer Cell Lines

US Patent:
2016006, Mar 10, 2016
Filed:
Aug 26, 2015
Appl. No.:
14/836927
Inventors:
- Philadelphia PA, US
Kerry S. Campbell - Wyncote PA, US
International Classification:
A61K 49/00
A61K 35/17
C12N 5/0783
A61K 39/395
Abstract:
The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD 16 (FcγRIII-A), or other Fcγ or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as FcεRI-γ,TCR-ζ, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.

Isbn (Books And Publications)

Natural Killer Cell Protocols: Cellular And Molecular Methods

Author:
Kerry S. Campbell
ISBN #:
0896036839

Possible Relatives

David D Campbell  Deanna M Campbell  Dagmar E Campbell  Dalia Campbell  Debby A Campbell  Damian J Campbell  Danette M Campbell  Kerry D Jones  Kerry J Stanger  Kerry J Stark 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.